Key regions: France, India, United Kingdom, South Korea, Japan
The demand for Multiple Sclerosis Drugs in Bhutan has been steadily increasing in recent years.
Customer preferences: Patients with Multiple Sclerosis in Bhutan prefer drugs that are effective in managing symptoms and improving their quality of life. They also prefer drugs that are affordable and have minimal side effects.
Trends in the market: The Multiple Sclerosis Drugs market in Bhutan has been growing due to the increasing prevalence of Multiple Sclerosis in the country. The government has also been taking steps to improve access to healthcare, which has led to an increase in the number of patients seeking treatment for Multiple Sclerosis. Additionally, there has been a growing awareness among patients about the importance of early diagnosis and treatment of Multiple Sclerosis, which has further contributed to the growth of the market.
Local special circumstances: Bhutan is a small country with a population of just over 750,000 people. The country has a limited healthcare infrastructure, which has led to challenges in providing timely and effective treatment to patients with Multiple Sclerosis. However, the government has been investing in improving healthcare infrastructure in recent years, which has led to an increase in the availability of healthcare services for patients with Multiple Sclerosis.
Underlying macroeconomic factors: Bhutan is a developing country with a small economy. The country has been experiencing steady economic growth in recent years, which has led to an increase in healthcare spending. Additionally, the government has been taking steps to improve access to healthcare services, which has led to an increase in the number of patients seeking treatment for Multiple Sclerosis. The growth of the Multiple Sclerosis Drugs market in Bhutan is expected to continue in the coming years, driven by the increasing prevalence of Multiple Sclerosis in the country and the government's focus on improving healthcare infrastructure.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
